Ticagrelor

Generic Name: Ticagrelor

Brand Names: Brilinta, Brilique

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₈F_₂N_₆O_₄S

CAS Number: 274693-27-5

Unique Ingredient Identifier: GLH0314RVC

Background: Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.

Ticagrelor was granted EMA approval on 3 December 2010.

Ticagrelor was granted FDA approval on 20 July 2011.

Indication: Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.

Associated Conditions: Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)

Associated Therapies: -

Clinical Trials

The ACS Ethnicity Platelet Function Study

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Ticagrelor

First Posted Date: 2013-04-11

Last Posted Date: 2018-06-08

Lead Sponsor: Medstar Health Research Institute

Target Recruit Count: 4

Registration Number: NCT01829659

Locations: 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States

Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study

Phase 4

Withdrawn

Conditions: Acute Coronary Syndrome
Coronary Artery Disease

Interventions: Drug: Ticagrelor
Drug: Clopidogrel
Device: Optical Coherence Tomography

First Posted Date: 2013-04-08

Last Posted Date: 2016-12-20

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT01826175

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Phase 3

Completed

Conditions: Coronary Artery Disease (CAD)

Interventions: Drug: Ticagrelor
Drug: Acetylsalicylic Acid
Drug: Clopidogrel

First Posted Date: 2013-03-19

Last Posted Date: 2022-03-15

Lead Sponsor: ECRI bv

Target Recruit Count: 15991

Registration Number: NCT01813435

Locations: 🇧🇪
Research centre Aalst, 3201, Aalst, Belgium
🇧🇪
Research centre Genk, 3205, Genk, Belgium
🇦🇹
Research centre Graz, 4305, Graz, Austria

and more 127 locations

Efficacy and Safety Study of Ticagrelor

Phase 3

Conditions: Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2013-03-18

Last Posted Date: 2015-06-24

Lead Sponsor: General Hospital of Chinese Armed Police Forces

Target Recruit Count: 180

Registration Number: NCT01812330

Locations: 🇨🇳
General Hospital of Chinese People's Armed Police Forces, Beijing, China

Effect of Ticagrelor on Endothelial Function

Phase 3

Completed

Conditions: Endothelial Function
Coronary Artery Disease

Interventions: Drug: clopidogrel
Drug: Ticagrelor

First Posted Date: 2013-03-06

Last Posted Date: 2016-10-05

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 45

Registration Number: NCT01805596

Locations: 🇨🇦
London Health Sciences Centre, London, Ontario, Canada

Rapid Activity of Platelet Inhibitor Drugs Study 2

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2013-03-06

Last Posted Date: 2014-09-25

Lead Sponsor: David Antoniucci

Target Recruit Count: 50

Registration Number: NCT01805570

Locations: 🇮🇹
Careggi Hospital, Florence, Italy

Cangrelor Ticagrelor Transition Study

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: cangrelor
Drug: Ticagrelor

First Posted Date: 2013-01-11

Last Posted Date: 2014-05-19

Lead Sponsor: The Medicines Company

Target Recruit Count: 12

Registration Number: NCT01766466

Locations: 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States

Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

Phase 3

Terminated

Conditions: Coronary Artery Disease
Stable Angina
Acute Coronary Syndrome

Interventions: Drug: Aspirin
Drug: Ticagrelor
Drug: Placebo - Ticagrelor
Drug: Placebo - Aspirin

First Posted Date: 2012-12-24

Last Posted Date: 2018-08-02

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 1893

Registration Number: NCT01755520

Locations: 🇩🇪
Universitätsklinikum Aachen, Aachen, Germany
🇩🇪
Deutsches Herzzentrum München, Munich, Bavaria, Germany
🇦🇹
Klinikum Wels-Grieskirchen, Wels, Austria

and more 26 locations

Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets

Phase 1

Completed

Conditions: Inhibition on Platelet Aggregation

Interventions: Drug: Ticagrelor
Drug: Clopidogrel
Drug: ASA

First Posted Date: 2012-12-06

Last Posted Date: 2014-04-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 258

Registration Number: NCT01744288

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Tailored Antiplatelet Therapy Following PCI

Phase 4

Completed

Conditions: Coronary Artery Disease
Stenosis
Acute Coronary Syndrome

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2012-12-05

Last Posted Date: 2021-11-09

Lead Sponsor: Mayo Clinic

Target Recruit Count: 5276

Registration Number: NCT01742117

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
The Feinstein Institute for Medical Research, Manhasset, New York, United States
🇨🇦
Humber River Hospital, Toronto, Ontario, Canada

and more 38 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy